作为抗癌药物的新型螺旋酸-皮拉诺皮拉醇混合物,具有潜在的TrkC抑制作用
Somayeh Mohammadi1, Motahareh Mortazavi1, Alireza Poustforoosh1
1Medicinal and Natural Products Chemistry Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.
Journal of biomolecular structure & dynamics
|March 3, 2025
概括
新型的螺旋酸衍生物对肺癌,结肠癌和胰腺癌细胞系表现出强大的抗癌活性. 这些化合物可能通过抑制热聚氨酸受体激酶C (TrkC) 起作用,为向癌症治疗提供了潜在的潜力.
科学领域:
- 药用化学 医学化学
- 药物发现 药物发现 药物发现
- 计算化学计算化学
背景情况:
- 癌症仍然是一个重大的全球健康挑战,死亡率高.
- 伊沙和皮拉的支架因其作为抗癌剂的潜力而得到认可.
- 为了有效治疗癌症,不断寻找新的化学实体.
研究的目的:
- 为了合成和评估一系列新的螺旋酸皮拉诺皮拉醇衍生物的抗癌活性.
- 研究最强效化合物的抗增殖作用背后的分子机制.
- 探索这些化合物作为向抗癌剂的潜力.
主要方法:
- 合成了15种新型的螺旋胺pyranopyrazole衍生物.
- 使用MTT测定对EBC-1,HT-29,A549和AsPC-1细胞系进行抗癌活性评估.
- 使用SuperPred,分子对接和分子动力学 (MD) 模拟进行in silico目标预测.
主要成果:
- 四种含化物衍生物 (6c, 6d, 6f, 6g) 对所有测试的癌症细胞系表现出显著的抗增殖作用.
- 这些强效化合物对EBC-1和HT-29细胞 (IC50值分别为3.3-7.1μM和7.3-10.2μM) 显示出高效,非癌细胞相对较少.
- 在分析中,推热氨酸受体激酶C (TrkC) 作为潜在的标,对接和MD模拟证实了强大的结合相互作用.
结论:
- 斯皮罗伊萨丁的pyranopyrazole类似物显示出有前途的抗癌潜力.
- 已识别的化合物表现出强有力的和选择性的抗增殖活性.
- 抑制TrkC是一种可能的作用机制,支持它们作为向抗癌剂的发展.
相关概念视频
Inhibition of Cdk Activity
4.6K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.6K
Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K
Combination Therapies and Personalized Medicine
4.8K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.8K
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
147
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...
147
Drugs that Stabilize Microtubules
2.0K
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.0K
Treatment Resistant Cancers
3.2K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.2K


